SUBSCRIBE
SUBSCRIBE

Phase 2

Drug Development
10 Drugs That Could be Johnson & Johnson’s New Blockbusters
November 2, 2016
 · 
1 min read
Gilead Goes Big, Pays $11.9 Billion for This SoCal CAR-T Biopharma
Drug Development
Gilead Looking Even Weaker on the R&D Front as It Racks Up Some More Clinical Failures in Q3 Report
November 2, 2016
 · 
3 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Drug Development
The $40 Billion NASH Market and the 3 Biotechs That Stand to Profit From it
November 1, 2016
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Drug Development
Why Biogen’s Fate May Depend on Eli Lilly’s Alzheimer’s Data
October 27, 2016
 · 
3 min read
Drug Development
A Look at BioMarin’s Potential Blockbuster and the Science Behind It All
October 21, 2016
 · 
1 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Business
Alkermes’ Success Puts the Spotlight on Cerecor, Eli Lilly’s 2015 Deal
October 21, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Roche’s Avastin Successor Flunks Key Study, Turns Hope to Tecentriq Instead
October 21, 2016
 · 
2 min read
Celgene Cuddles Up With Another Cambridge Biotech, This Time to Tackle Autoimmune Diseases
Drug Development
What You May Have Missed: Critics Point to Problems With Celgene’s Crohn’s Drug Trial Design
October 19, 2016
 · 
3 min read
Why Booming Vertex is on Its Way to Becoming Gilead's Mini-Me
Drug Development
After Hep C Flop, Has Vertex Learned From Its Past Mistakes?
October 18, 2016
 · 
3 min read
For Sale: Pfizer's $3.4 Billion Consumer Healthcare Business
Drug Development
How Pfizer is Quietly Rebuilding Its Alzheimer’s Pipeline
October 18, 2016
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
 · 
18 min read
Press Releases
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
May 7, 2026
 · 
7 min read
Press Releases
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
May 7, 2026
 · 
1 min read
Press Releases
Bioxodes presents positive final Phase 2a intracerebral hemorrhage results at ESOC affirming breakthrough potential of BIOX-101
May 6, 2026
 · 
5 min read
Press Releases
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
May 6, 2026
 · 
10 min read
Press Releases
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026
 · 
14 min read
Press Releases
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
May 6, 2026
 · 
10 min read
Press Releases
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
May 6, 2026
 · 
12 min read
Press Releases
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
May 6, 2026
 · 
11 min read
Press Releases
Immunocore reports first quarter 2026 financial results and provides a business update
May 6, 2026
 · 
22 min read
Press Releases
Spago Nanomedical’s Phase I/IIa study Tumorad-01 Meets a Primary Endpoint and Provides Further Visible Tumor Uptake
May 6, 2026
 · 
3 min read
Press Releases
MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
May 6, 2026
 · 
2 min read
Press Releases
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
May 6, 2026
 · 
14 min read
Press Releases
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients
May 6, 2026
 · 
5 min read
Press Releases
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
May 6, 2026
 · 
15 min read
Press Releases
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
May 6, 2026
 · 
10 min read
Press Releases
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
May 6, 2026
 · 
6 min read
Press Releases
Nocion Therapeutics Announces Full Enrollment in Phase 2b ASPIRE Study of Taplucainium for Chronic Cough
May 5, 2026
 · 
3 min read
Press Releases
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
May 5, 2026
 · 
8 min read
Press Releases
Neuraly, Inc. Supports Phase 2 Investigator-Initiated Trial of Pegsebrenatide (NLY01) for Progressive Multiple Sclerosis
May 5, 2026
 · 
3 min read
Load More